Phase 3 COMET trials of dry eye candidate meet primary endpoint

Two pivotal phase 3 clinical trials evaluating the efficacy and safety of AR-15512 for treating the signs and symptoms of dry eye disease achieved the primary endpoint, according to a press release from Alcon.
The COMET-2 and COMET-3 trials enrolled and randomly assigned more than 930 participants with dry eye disease to treatment with either AR-15512, a topical transient receptor potential melastatin 8 agonist, or vehicle control.
The primary endpoint of both trials was the proportion of subjects with at least a 10 mm increase in unanesthetized Schirmer’s score, and this was achieved

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.